C12N2760/20234

Recombinant viral vectors

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

VESICULAR STOMATITIS VECTORS ENCODING CRIMEAN-CONGO HEMORRHAGIC FEVER ANTIGEN

Certain embodiments are directed generally to compositions and methods related to recombinant vesicular stomatitis virus vectors (GrVSV) encoding Crimean-Congo Hemorrhagic Fever glycoprotein precursor (CCHFV-GPC) and forming a recombinant vesicular stomatitis virus vector encoding Crimean-Congo Hemorrhagic Fever glycoprotein precursor (GrVSV-CCHFV-GPC).

COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION

Provided are compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.

Chimeric VSV virus compositions and methods of use thereof for treatment of cancer
10821143 · 2020-11-03 · ·

Methods of treating cancer including administering to a subject with cancer a pharmaceutical composition including an effective amount of a chimeric VSV virus are disclosed. The chimeric viruses are based on a VSV background where the VSV G protein is replaced with one or more heterologous viral glycoproteins. In the most preferred embodiment, the VSV G protein is replaced with the glycoprotein from Lassa virus or a functional fragment thereof. The resulting chimeric virus is an oncolytic virus that is attenuated and safe in the brain, yet still retains sufficient oncolytic activity to infect and destroy cancer cells such glioblastoma, and to generate an immune response against infected cancer cells. Methods of using chimeric viruses as a platform for immunization against other pathogenic microbes are also provided.

Activation of resident memory T cells for cancer immunotherapy

Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.

MODIFIED VSV-G AND VACCINES THEREOF

A modified vesicular stomatitis virus glycoprotein (VSV-G) that includes at least one peptide, preferably an antigen or fragment thereof, nucleic acid sequence coding therefor, and vectors containing the nucleic acid sequence. Also vaccines and methods for the treatment of a disease or condition, in particular a cancer or an infectious disease.

Compositions and methods for viral sensitization

Provided are compounds of Formula (II) that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided. Compounds of Formula (II): ##STR00001##

ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPY
20240041996 · 2024-02-08 ·

Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.

Recombinant viral vectors

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

ZIKA VIRUS VACCINE
20190255170 · 2019-08-22 ·

Compositions and methods useful for treating and/or preventing a Zika virus infection are provided.